Edition:
United Kingdom

LivaNova PLC (LIVN.OQ)

LIVN.OQ on NASDAQ Stock Exchange Global Select Market

85.85USD
16 Feb 2018
Change (% chg)

$0.04 (+0.05%)
Prev Close
$85.81
Open
$85.50
Day's High
$86.80
Day's Low
$85.28
Volume
118,210
Avg. Vol
133,071
52-wk High
$88.42
52-wk Low
$47.01

Select another date:

Thu, Feb 15 2018

BRIEF-Livanova To Acquire Tandemlife

* LIVANOVA PLC - LIVANOVA HAS AGREED TO PAY UP TO $250 MILLION FOR TANDEMLIFE

BRIEF-Livanova Initiates Believe Aortic Heart Valve Study In The U.S., Canada

* LIVANOVA INITIATES BELIEVE AORTIC HEART VALVE STUDY IN THE U.S. AND CANADA

BRIEF-LivaNova Commences Global Restore-Life Study For Treatment-Resistant Depression

* LIVANOVA COMMENCES GLOBAL RESTORE-LIFE STUDY FOR TREATMENT-RESISTANT DEPRESSION Source text for Eikon: Further company coverage:

BRIEF-Livanova To Acquire Imthera Medical

* LIVANOVA PLC SAYS ENTERED INTO AN AGREEMENT TO ACQUIRE REMAINING OUTSTANDING INTERESTS IN IMTHERA MEDICAL, INC.

BRIEF-Microport Scientific's unit buys CRM business from Livanova

* ‍Unit buys CRM business for initial consideration of US$190 million​ from Livanova PLC Source text for Eikon: Further company coverage: (bangalore.newsroom@thomsonreuters.com)

BRIEF-LivaNova Plc reports ‍Q3 diluted earnings per share were $0.57​

* LivaNova Plc - ‍Q3 2017 diluted earnings per share were $0.57​

BRIEF-Livanova receives FDA approval for Vagus Nerve Stimulation Therapy system​

* Livanova receives FDA approvals for SenTiva device and next-generation VNS therapy programming system for treatment of epilepsy

BRIEF-Livanova and Microport announce approval of Rega pacemakers by China FDA

* Livanova and Microport announce the approval of Rega pacemakers by the China Food and Drug Administration

BRIEF-Livanova announces U.S. Launch of Optiflow Arterial Cannulae Family

* Says ‍received FDA 510(k) clearance for U.S. Market launch of its Optiflow Arterial Cannulae Family​ Source text for Eikon: Further company coverage:

BRIEF-LivaNova ‍expects to achieve revenue growth in mid-single-digits in near term and high-single-digits in long term​

* LivaNova Plc - ‍Expects to achieve revenue growth in mid-single-digits in near term and high-single-digits in long term​

Select another date: